Trials / Completed
CompletedNCT04555148
COVIDIG (COVID-19 Hyper-ImmunoGlobulin)
A Prospective, Open-label, Randomized, Multi-center, Phase 2a Study to Evaluation the Dose Response, Efficacy and Safety of Hyper-Ig (Hyper-immunoglobulin) GC5131 in Patients With COVID-19
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Green Cross Corporation · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy and safety of 5131A for hospitalized patients of COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GC5131 | COVID19 Hyper-Immunoglobulin |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2020-09-19
- Primary completion
- 2021-01-22
- Completion
- 2021-04-23
- First posted
- 2020-09-18
- Last updated
- 2021-08-24
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04555148. Inclusion in this directory is not an endorsement.